Camargo JF, Komanduri KV. Rising ideas in cytomegalovirus an infection following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10:233–8.
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus an infection and illness in transplant sufferers to be used in medical trials. Clin Infect Dis. 2017;64:87–91.
Einsele H, Ljungman P, Boeckh M. How I deal with CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood 2020;135:1619–29.
Jerry Teng CL, Wang PN, Chen YC, Ko BS. Cytomegalovirus administration after allogeneic hematopoietic stem cell transplantation: a mini-review. J Microbiol Immunol Infect. 2021;54:341–8.
Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus ailments after hematopoietic stem cell transplantation: a mini-review. Most cancers Lett. 2014;342:1–8.
Jakharia N, Howard D, Riedel DJ. CMV an infection in hematopoietic stem cell transplantation: prevention and remedy methods. Curr Deal with Choices Infect Dis. 2021;13:123–40.
Mori T, Kato J. Cytomegalovirus an infection/illness after hematopoietic stem cell transplantation. Int J Hematol. 2010;91:588–95.
Limaye AP, Babu TM, Boeckh M. Progress and challenges within the prevention, prognosis, and administration of cytomegalovirus an infection in transplantation. Clin Microbiol Rev. 2020;34:e00043–19.
Bueno F, Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, et al. Evaluation of the affiliation between cytomegalovirus DNAemia and subsequent acute graft-versus-host illness in allogeneic peripheral blood stem cell transplantation: A multicenter research from the Spanish hematopoietic transplantation and cell remedy group. Transpl Infect Dis. 2021;23:e13627.
Yong MK, Ananda-Rajah M, Cameron PU, Morrissey CO, Spencer A, Ritchie D, et al. Cytomegalovirus reactivation is related to elevated danger of late-onset invasive fungal illness after allogeneic hematopoietic stem cell transplantation: a multicenter research within the present period of viral load monitoring. Biol Blood Marrow Transpl. 2017;23:1961–7.
Boeckh M, Murphy WJ, Peggs KS. Reprint of: Current advances in cytomegalovirus: an replace on pharmacologic and mobile therapies. Biol Blood Marrow Transpl. 2015;21:S19–24.
Anderson A, Raja M, Vazquez N, Morris M, Komanduri Ok, Camargo J. Scientific “real-world” expertise with letermovir for prevention of cytomegalovirus an infection in allogeneic hematopoietic cell transplant recipients. Clin Transpl. 2020;34:e13866.
Mori Y, Harada T, Yoshimoto G, Shima T, Numata A, Jinnouchi F, et al. Threat components for late cytomegalovirus an infection after finishing letermovir prophylaxis. Int J Hematol. 2022;116:258–65.
Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, et al. A mortality evaluation of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2020;70:1525–33.
El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, et al. The flexibility of a cytomegalovirus ELISPOT assay to foretell end result of low-level CMV reactivation in hematopoietic cell transplant recipients. J Infect Dis. 2019;219:898–907.
Lee SM, Kim YJ, Yoo KH, Sung KW, Koo HH, Kang ES. Scientific usefulness of monitoring cytomegalovirus-specific immunity by quantiferon-CMV in pediatric allogeneic hematopoietic stem cell transplantation recipients. Ann Lab Med. 2017;37:277–81.
Chemaly RF, El Haddad L, Winston DJ, Rowley SD, Mulane KM, Chandrasekar P, et al. Cytomegalovirus (CMV) cell-mediated immunity and CMV an infection after allogeneic hematopoietic cell transplantation: the REACT research. Clin Infect Dis. 2020;71:2365–74.
Kawamura S, Nakasone H, Takeshita J, Kimura SI, Nakamura Y, Kawamura M, et al. Prediction of cytomegalovirus reactivation by recipient cytomegalovirus-IgG titer earlier than allogeneic hematopoietic stem cell transplantation. Transpl Cell Ther 2021;27:683.e1–e7.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Illness Threat Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
Thompson G, Boan P, Purtill D, Cooney J, Cannell P, Wright M, et al. QuantiFERON-cytomegalovirus to foretell clinically important cytomegalovirus an infection after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2022;24:e13786.
Nam M, Track DY, Track SH, Roh EY, Shin S, Park KU, et al. Efficiency analysis of immunoassay for infectious ailments on the Alinity i system. J Clin Lab Anal. 2021;35:e23671.
Juhl D, Vockel A, Luhm J, Ziemann M, Hennig H, Görg S. Comparability of the 2 absolutely automated anti-HCMV IgG assays: Abbott Architect CMV IgG assay and Biotest anti-HCMV recombinant IgG ELISA. Transfus Med. 2013;23:187–94.
George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, et al. Pre-transplant cytomegalovirus (CMV) serostatus stays crucial determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation within the period of surveillance and preemptive remedy. Transpl Infect Dis. 2010;12:322–9.
Yong MK, Lewin SR, Manuel O. Immune monitoring for CMV in transplantation. Curr Infect Dis Rep. 2018;20:4.
Arcuri LJ, Schirmer M, Colares M, Maradei S, Tavares R, Moreira MCR, et al. Influence of Anti-CMV IgG titers and CD34 depend previous to hematopoietic stem cell transplantation from various donors on CMV reactivation. Biol Blood Marrow Transpl. 2020;26:e275–e9.
Inexperienced ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation within the period of pre-emptive remedy: a retrospective cohort research. Lancet Haematol. 2016;3:e119–27.
Ostrovsky O, Beider Ok, Morgulis Y, Bloom N, Cid-Arregui A, Shimoni A, et al. CMV seropositive standing will increase heparanase SNPs regulatory exercise, danger of acute GVHD and yield of CD34(+) cell mobilization. Cells. 2021;10:3489.
La Rosa C, Diamond DJ. The immune response to human CMV. Future Virol. 2012;7:279–93.
Herling M, Schröder L, Awerkiew S, Chakupurakal G, Holtick U, Kaiser R, et al. Persistent CMV an infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Improvement of multidrug resistance within the absence of anti-viral mobile immunity. J Clin Virol. 2016;74:57–60.
Mehta RS, Rezvani Ok. Immune reconstitution put up allogeneic transplant and the influence of immune restoration on the chance of an infection. Virulence. 2016;7:901–16.
Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus within the immunocompromised host. Nat Rev Microbiol. 2021;19:759–73.
Boeckh M, Nichols WG. The influence of cytomegalovirus serostatus of donor and recipient earlier than hematopoietic stem cell transplantation within the period of antiviral prophylaxis and preemptive remedy. Blood. 2004;103:2003–8.
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.
Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, et al. Elevated transplant-related morbidity and mortality in CMV-seropositive sufferers regardless of extremely efficient prevention of CMV illness after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240–5.
Ljungman P, Model R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic standing and end result of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile evaluation. Blood. 2003;102:4255–60.
Kalra A, Williamson T, Daly A, Savoie ML, Stewart DA, Khan F, et al. Influence of donor and recipient cytomegalovirus serostatus on outcomes of antithymocyte globulin-conditioned hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22:1654–63.
Ljungman P, Model R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al. Donor cytomegalovirus standing influences the end result of allogeneic stem cell transplant: a research by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59:473–81.
Khamis H. Measures of affiliation: how to decide on? J Diagnostic Med Sonography. 2008;24:155–62.
